EPZM News and Press, Epizyme Inc. From 11/09/21

Start Time: 08:30 End Time: 09:03 Epizyme, Inc. (EPZM) Q3 2021 Earnings Conference Call November 09, 2021, 08:30 AM ET Company Participants Grant Bogle - President and CEO Shefali Agarwal - EVP, Chief Medical and Development Officer Craig West - VP, IR Conference Call Participants Peter Lawso...

Epizyme (NASDAQ:EPZM): Q3 GAAP EPS of -$0.64 misses by $0.11. Revenue of $5.2M (+45.7% Y/Y) misses by $3.45M. Shares +1.61% PM. Press Release For further details see: Epizyme EPS misses by $0.11, misses on revenue

-- TAZVERIK ® (tazemetostat) Net Product Revenues of $5.2 Million; End User Demand Grew 22% -- -- Received $25 Million Upfront Payment from HUTCHMED License Agreement -- -- SYMPHONY-1 (EZH-302) Preparing for Phase 3 Initiation; SETD2 Phase 1/1b Study Initiated...

Epizyme (NASDAQ:EPZM) is scheduled to announce Q3 earnings results on Tuesday, November 9th, before market open. The consensus EPS Estimate is -$0.44 (+20.0% Y/Y) and the consensus Revenue Estimate is $8.65M (+142.3% Y/Y). Over the last 1 year, EPZM has beaten EPS estimates 75% of the time an...

Epizyme (NASDAQ:EPZM) announces that the U.S. FDA has granted Fast Track designation to EZM0414, the company’s novel, first-in-class, oral SETD2 inhibitor, as an investigational agent for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DL...

Epizyme, Inc. (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to EZM0414, the Company’s novel, ...

Epizyme , (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that management will host a conference call to discuss its third quarter 2021 financial results and provide a business updat...

Epizyme today announced the launch of In My Blood , an online resource designed to empower people living with follicular lymphoma to partner with their healthcare providers and play a proactive role in treatment decision-making based on where they are in their follicular lym...

Two Poster Presentations for Tazemetostat, a Methyltransferase Inhibitor, in Metastatic Castration-Resistant Prostate Cancer and in Combinations in Patients with Solid Tumors Epizyme, Inc. (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company develop...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...